San Francisco-based OmicsBank, a clinical data infrastructure company founded in 2025, has announced $2.25 million in seed funding from Redesign Health. The investment will support U.S. expansion across health systems, pharmaceutical and biotechnology companies, CROs, and AI developers while extending its clinical data network in Asia and the Middle East. The company connects fragmented hospital data for drug development and healthcare AI, standardizing and de-identifying multimodal information at the source across more than 90 hospitals and diagnostic labs in Asia.
Closing the Global Data Representation Gap
Drug development and healthcare AI have relied heavily on clinical and genomic datasets from the U.S. and Europe, leaving many global populations underrepresented. India and South Asia account for a large share of the global population, yet they participate in approximately 2 percent or less of large-scale global genomic research. Sumit Sinha, Co-Founder and CEO, said the data powering drug development and healthcare AI still represents a narrow slice of the world, and OmicsBank is building infrastructure to close that gap.
Standardizing Fragmented Hospital Data
Hospital data remains fragmented across electronic health records, labs, imaging, pathology, and other systems, making longitudinal patient records difficult to build. This fragmentation has limited researchers' ability to tap the scale and diversity of clinical data across Asia, the U.S., and the EU. OmicsBank standardizes and de-identifies information within the hospital environment, linking clinical events with imaging and multi-omics data to create research-ready multimodal records for pharmaceutical, biotechnology, and AI teams.
Scale and Breadth of the Clinical Data Network
Founded in 2025 by Sumit Sinha and Vijay Goel, the company's technology now sits inside more than 90 hospitals and diagnostic labs in Asia. Its ecosystem currently includes longitudinal EHR data from 12.5 million patients, more than 30 million DICOM images, 6 million pathology slides, and 500,000 genome sequences. OmicsBank is already working with pharmaceutical and biotechnology companies on real-world evidence studies across oncology, neurology, cardiology, nephrology, endocrinology, immunology, and dermatology.
Supporting Drug Development and Healthcare AI
The company is also working with frontier AI organizations on pre-training, post-training, and reinforcement learning for clinical and multimodal models. Its data supports disease, biomarker, and treatment response studies while enabling evaluation and training of medical AI models. For pharmaceutical and biotech teams, OmicsBank offers research-ready multimodal data to inform drug development and generate real-world evidence across many therapeutic areas.
A Two-Sided U.S. Expansion Strategy
In the U.S., OmicsBank is providing pharmaceutical, biotechnology, CRO, and frontier AI organizations with research-ready data from Asia. The company is also partnering with U.S. health systems to build research-ready data infrastructure and bring additional populations into its standardized, longitudinal data network across multiple care settings. This two-sided strategy creates opportunities for cross-population and cross-geography research using multimodal, multi-omics data.
Investor Perspectives on Global Scale
Neil Patel, Head of Ventures at Redesign Health, said the firm underwrote founders Sumit Sinha and Vijay Goel first and the market second. Patel noted that the lack of well-structured, representative clinical data is becoming a constraint on drug development and research. Oscar Ramos Moreno, Managing General Partner at Orbit Ventures, added that making medical research more representative of emerging-market populations is a matter of inclusion and global health improvement.
Growth Plans and Computational Infrastructure
With the new funding, OmicsBank will expand its hospital network across the U.S., the Middle East, and Southeast Asia while growing relationships with pharmaceutical, biotechnology, and AI companies. The company is also developing GPU-enabled research environments for AI model training, reinforcement learning environments, biomarker discovery, real-world evidence, and computational biology research. These capabilities aim to support more diverse data foundations for drug development and healthcare AI.
OmicsBank's seed funding highlights growing demand for clinical data infrastructure that broadens representation in drug development and artificial intelligence. By connecting fragmented hospital data across Asia, the Middle East, and the United States, the company aims to support more inclusive research while enabling advanced model training and real-world evidence studies. The expansion could help researchers, health systems, and AI developers access a richer and more diverse picture of human health.